ALT (A) Estimated mean change in bodyweight by treatment week (efficacy estimand). (B) Least squares mean change in bodyweight from baseline to week 42 (efficacy estimand). (C) Observed mean change in bodyweight by treatment week (treatment policy estimand). (D) Least squares mean change in bodyweight (%) from baseline to week 42 (treatment policy estimand). *p<0·0001 for difference versus placebo. †Treatment policy estimates at week 42.

ALT Colour coding reflects the overall direction of available evidence and does not account for heterogeneity between trials or differences in effect size. Green dot: currently available trials indicate exclusively or predominantly beneficial effects. Yellow dot: currently available trials indicate varying effects (or results are interpretable in varying ways), where evidence does altogether not indicate clear beneficial or clear adverse effects. Red dot: currently available trials indicate exclusively or predominantly adverse effects. Grey dot: currently available trials have not detected an effect on the outcome. White dot: unknown, currently no trials available.